Study: NCT01721317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available